Royalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results

Royalty Pharma (NASDAQ:RPRX) posted its earnings results on Tuesday. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16, Zacks reports. Royalty Pharma had a return on equity of 24.65% and a net margin of 50.53%.

Royalty Pharma Trading Up 1.7 %

Shares of RPRX stock opened at $32.25 on Wednesday. The stock has a market cap of $19.00 billion, a price-to-earnings ratio of 16.71 and a beta of 0.49. The stock has a 50-day moving average of $27.93 and a 200-day moving average of $27.65. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma has a 1-year low of $24.05 and a 1-year high of $32.72.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a $0.22 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.73%. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Wall Street Analysts Forecast Growth

Several research firms have commented on RPRX. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, Citigroup dropped their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Royalty Pharma currently has an average rating of “Buy” and an average target price of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.